Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an expanded phase II trial of patients with relapsed or...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Dotan, Efrat, Cohen, Steven J., Starodub, Alexander N., Lieu, Christopher H., Messersmith, Wells A., Simpson, Pamela S., Guarino, Michael J., Marshall, John L., Goldberg, Richard M., Hecht, J. Randolph, Wegener, William A., Sharkey, Robert M., Govindan, Serengulam V., Goldenberg, David M., Berlin, Jordan D.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2017
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8259133/
https://ncbi.nlm.nih.gov/pubmed/28817371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.9011
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires